NASDAQ:SRTS - Sensus Healthcare Stock Price, Forecast & News

Sensus Healthcare trades on the NASDAQ under the ticker symbol "SRTS."

Sensus Healthcare Inc (NASDAQ:SRTS) issued its quarterly earnings data on Thursday, February, 13th. The company reported $0.06 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.03 by $0.03. The company earned $8.51 million during the quarter, compared to analyst estimates of $8.45 million. Sensus Healthcare had a negative return on equity of 6.27% and a negative net margin of 6.24%. View Sensus Healthcare's Earnings History.

Sensus Healthcare is scheduled to release their next quarterly earnings announcement on Thursday, May 14th 2020. View Earnings Estimates for Sensus Healthcare.

5 equities research analysts have issued 12 month price targets for Sensus Healthcare's shares. Their forecasts range from $5.50 to $11.00. On average, they anticipate Sensus Healthcare's share price to reach $7.63 in the next year. This suggests a possible upside of 64.3% from the stock's current price. View Analyst Price Targets for Sensus Healthcare.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sensus Healthcare in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sensus Healthcare.

Headlines about SRTS stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Sensus Healthcare earned a media sentiment score of 1.8 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Sensus Healthcare.

Sensus Healthcare saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 141,300 shares, an increase of 31.7% from the January 15th total of 107,300 shares. Based on an average daily trading volume, of 30,600 shares, the short-interest ratio is presently 4.6 days. Approximately 1.2% of the shares of the stock are short sold. View Sensus Healthcare's Current Options Chain.

Some companies that are related to Sensus Healthcare include Iradimed (IRMD), SeaSpine (SPNE), Apyx Medical (APYX), Westaim (WEDXF), GenMark Diagnostics (GNMK), Repro Med Systems (KRMD), Repro-Med Systems (REPR), iCAD (ICAD), Venus Concept (VERO), Vapotherm (VAPO), Soliton (SOLY), RenovaCare (RCAR), TELA Bio (TELA), Pulse Biosciences (PLSE) and Cytosorbents (CTSO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Sensus Healthcare investors own include Zynerba Pharmaceuticals (ZYNE), Ring Energy (REI), Ring Energy (REI), Viking Therapeutics (VKTX), Agile Therapeutics (AGRX), Inovio Pharmaceuticals (INO), Melinta Therapeutics (MLNT), Nabriva Therapeutics (NBRV), Selecta Biosciences (SELB) and Sangamo Therapeutics (SGMO).

(SRTS) raised $20 million in an initial public offering (IPO) on Wednesday, March 30th 2016. The company issued 1,800,000 shares at $10.00-$12.00 per share. Joseph Gunnar and Feltl and Company served as the underwriters for the IPO and Neidiger, Tucker, Bruner was co-manager.

Sensus Healthcare's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Perkins Capital Management Inc. (1.44%), Perritt Capital Management Inc. (0.68%), Garrison Bradford & Associates Inc. (0.37%), Essex Investment Management Co. LLC (0.28%), Mairs & Power INC (0.08%) and Virtu Financial LLC (0.06%). Company insiders that own Sensus Healthcare stock include Arthur Levine, Joseph C Sardano, Kalman Fishman, Richard Golin and Stephen Brad Cohen. View Institutional Ownership Trends for Sensus Healthcare.

SRTS stock was sold by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc., Essex Investment Management Co. LLC and Perritt Capital Management Inc.. Company insiders that have sold Sensus Healthcare company stock in the last year include Kalman Fishman, Richard Golin and Stephen Brad Cohen. View Insider Buying and Selling for Sensus Healthcare.

SRTS stock was purchased by a variety of institutional investors in the last quarter, including Mairs & Power INC, Virtu Financial LLC, Tower Research Capital LLC TRC and Garrison Bradford & Associates Inc.. View Insider Buying and Selling for Sensus Healthcare.

Shares of SRTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SRTS stock can currently be purchased for approximately $4.64.

Sensus Healthcare has a market capitalization of $76.56 million and generates $27.26 million in revenue each year. The company earns $-1,700,000.00 in net income (profit) each year or ($0.10) on an earnings per share basis. Sensus Healthcare employs 48 workers across the globe.View Additional Information About Sensus Healthcare.

The official website for Sensus Healthcare is http://www.sensushealthcare.com/.

Sensus Healthcare's mailing address is 851 BROKEN SOUND PARKWAY NW SUITE 215, BOCA RATON FL, 33487. The company can be reached via phone at 561-922-5808 or via email at [email protected]